The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a greater substantial loss in body size and enhance metabolic function, p